Data / Drug companies / Upsher-Smith Laboratories, LLC
Upsher-Smith Laboratories, LLC: 45 products in the FDA NDC directory, labeler code 0245
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Upsher-Smith Laboratories, LLC (labeler code 0245) lists 45 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 45 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 5, 2026.
The request: Watch Upsher-Smith Laboratories, LLC (FDA labeler code 0245): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0245
- Products in commercial distribution
- 45
- Packages
- 90
- Finished drugs by generic name
- 15
- Prescription products
- 45
- Over the counter products
- 0
- Controlled substance products
- Schedule II 3, Schedule III 2
- Flagged as original packager
- 43 of 43 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 4
- Earliest marketing start
- April 17, 1986
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 31 | 68.9% |
| New drug applications (NDA) | 13 | 28.9% |
| Other unapproved drugs | 1 | 2.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 45 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Potassium chloride | 8 | 84 |
| Deflazacort | 5 | 11 |
| Topiramate | 5 | 56 |
| Everolimus | 4 | 15 |
| Isotretinoin | 4 | 16 |
| Hydrocodone bitartrate and acetaminophen | 3 | 37 |
| Midodrine hydrochloride | 3 | 34 |
| Amiodarone hydrochloride | 3 | 35 |
| Vigabatrin | 2 | 18 |
| Potassium citrate | 2 | 17 |
| Testosterone | 2 | 22 |
| Metronidazole | 1 | 68 |
| Cholestyramine | 1 | 14 |
| Sumatriptan | 1 | 28 |
| Potassium bicarbonate | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 20 | 44.4% |
| Capsule, extended release | 5 | 11.1% |
| Tablet, film coated, extended release | 4 | 8.9% |
| Capsule, liquid filled | 4 | 8.9% |
| Tablet, extended release | 3 | 6.7% |
| Gel | 2 | 4.4% |
| Powder, for solution | 2 | 4.4% |
| Powder, for suspension | 1 | 2.2% |
| Spray | 1 | 2.2% |
| Suspension | 1 | 2.2% |
| Gel, metered | 1 | 2.2% |
| Tablet, effervescent | 1 | 2.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Kymbee | 0245-0813 | Suspension | Generic drugs (ANDA) | June 5, 2026 |
| Klor-con | 0245-0836 | Tablet, film coated, extended release | Generic drugs (ANDA) | August 15, 2025 |
| Klor-con | 0245-0835 | Tablet, film coated, extended release | Generic drugs (ANDA) | August 15, 2025 |
| Kymbee | 0245-0817 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Kymbee | 0245-0816 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Kymbee | 0245-0815 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Kymbee | 0245-0814 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Vigadrone | 0245-6001 | Tablet | Generic drugs (ANDA) | June 29, 2023 |
| Torpenz | 0245-0825 | Tablet | Generic drugs (ANDA) | October 1, 2021 |
| Torpenz | 0245-0824 | Tablet | Generic drugs (ANDA) | October 1, 2021 |
| Torpenz | 0245-0823 | Tablet | Generic drugs (ANDA) | October 1, 2021 |
| Torpenz | 0245-0822 | Tablet | Generic drugs (ANDA) | October 1, 2021 |
| Isotretinoin | 0245-0573 | Capsule, liquid filled | Generic drugs (ANDA) | September 21, 2021 |
| Isotretinoin | 0245-0571 | Capsule, liquid filled | Generic drugs (ANDA) | September 21, 2021 |
| Isotretinoin | 0245-0570 | Capsule, liquid filled | Generic drugs (ANDA) | September 21, 2021 |
| Isotretinoin | 0245-0575 | Capsule, liquid filled | Generic drugs (ANDA) | April 12, 2021 |
| Pacerone | 0245-1645 | Tablet | Generic drugs (ANDA) | July 2, 2020 |
| Tosymra | 0245-0812 | Spray | New drug applications (NDA) | July 8, 2019 |
| Vigadrone | 0245-0556 | Powder, for solution | Generic drugs (ANDA) | June 21, 2018 |
| Klor-con | 0245-0360 | Powder, for solution | Generic drugs (ANDA) | October 23, 2017 |
| Hydrocodone Bitartrate and Acetaminophen | 0245-0412 | Tablet | Generic drugs (ANDA) | March 27, 2017 |
| Hydrocodone Bitartrate and Acetaminophen | 0245-0411 | Tablet | Generic drugs (ANDA) | March 27, 2017 |
| Hydrocodone Bitartrate and Acetaminophen | 0245-0410 | Tablet | Generic drugs (ANDA) | March 27, 2017 |
| KLOR-Con/EF | 0245-5326 | Tablet, effervescent | Other unapproved drugs | September 1, 2014 |
| Vogelxo | 0245-0872 | Gel, metered | New drug applications (NDA) | June 9, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.